BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25971309)

  • 1. NOB1 expression predicts early response to cisplatin-based chemotherapy in patients with advanced non-small cell lung cancer.
    Liu K; Chen HL; Gu MM; You QS
    J Chemother; 2016 Jun; 28(3):225-9. PubMed ID: 25971309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between NOB1 expression and prognosis of resected non-small cell lung cancer.
    Liu K; Chen HL; Gu MM; You QS
    Int J Biol Markers; 2015 Feb; 30(1):e43-8. PubMed ID: 25450647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
    Liu K; Chen HL; Gu MM; You QS
    Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
    Du G; Yang Y; Zhang Y; Sun T; Liu W; Wang Y; Li J; Zhang H
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):893-904. PubMed ID: 23355038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FANCD2 expression in advanced non-small-cell lung cancer and response to platinum-based chemotherapy.
    Ferrer M; Span SW; Vischioni B; Oudejans JJ; van Diest PJ; de Winter JP; Giaccone G; Kruyt FA
    Clin Lung Cancer; 2005 Jan; 6(4):250-4. PubMed ID: 15694018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer.
    Lin TC; Tsai LH; Chou MC; Chen CY; Lee H
    Tumour Biol; 2016 Mar; 37(3):4017-23. PubMed ID: 26482622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FATS expression is associated with cisplatin sensitivity in non small cell lung cancer.
    Tian Y; Zhang J; Yan S; Qiu L; Li Z
    Lung Cancer; 2012 Jun; 76(3):416-22. PubMed ID: 22137560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Expression of RIOK2 and NOB1 Predict Human Non-small Cell Lung Cancer Outcomes.
    Liu K; Chen HL; Wang S; Gu MM; Chen XM; Zhang SL; Yu KJ; You QS
    Sci Rep; 2016 Jun; 6():28666. PubMed ID: 27346559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NOB1 in non-small-cell lung cancer: expression profile and clinical significance.
    Liu K; Gu MM; Chen HL; You QS
    Pathol Oncol Res; 2014 Apr; 20(2):461-6. PubMed ID: 24272676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients.
    Chen P; Li J; Ge LP; Dai CH; Li XQ
    Respirology; 2010 Apr; 15(3):501-9. PubMed ID: 20210890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in Non-small cell lung cancer.
    Wu F; Lu M; Qu L; Li DQ; Hu CH
    Int J Clin Exp Pathol; 2015; 8(5):5457-63. PubMed ID: 26191250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
    O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R
    Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High ABCG4 Expression Is Associated with Poor Prognosis in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin-Based Chemotherapy.
    Yang G; Wang XJ; Huang LJ; Zhou YA; Tian F; Zhao JB; Chen P; Liu BY; Wen MM; Li XF; Zhang ZP
    PLoS One; 2015; 10(8):e0135576. PubMed ID: 26270652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
    Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
    Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Fiala O; Pesek M; Skrickova J; Kolek V; Salajka F; Tomiskova M; Satankova M; Kultan J; Kuliskova J; Svaton M; Hrnciarik M; Hejduk K; Chloupkova R; Topolcan O; Hornychova H; Nova M; Ryska A; Finek J
    Tumour Biol; 2017 Feb; 39(2):1010428317691186. PubMed ID: 28218046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status.
    Ikeda S; Yoshioka H; Ikeo S; Morita M; Sone N; Niwa T; Nishiyama A; Yokoyama T; Sekine A; Ogura T; Ishida T
    BMC Cancer; 2017 Nov; 17(1):797. PubMed ID: 29183294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
    Filipits M; Pirker R; Dunant A; Lantuejoul S; Schmid K; Huynh A; Haddad V; André F; Stahel R; Pignon JP; Soria JC; Popper HH; Le Chevalier T; Brambilla E
    J Clin Oncol; 2007 Jul; 25(19):2735-40. PubMed ID: 17602078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy.
    Saijo T; Ishii G; Ochiai A; Yoh K; Goto K; Nagai K; Kato H; Nishiwaki Y; Saijo N
    Lung Cancer; 2006 Nov; 54(2):217-25. PubMed ID: 16934364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.